Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. / Nøhr-Nielsen, Asbjørn; Bagger, Sofie Otzen; Brünner, Nils; Stenvang, Jan; Lund, Trine Meldgaard.

I: European Journal of Pharmaceutical Sciences, Bind 148, 105315, 2020.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Nøhr-Nielsen, A, Bagger, SO, Brünner, N, Stenvang, J & Lund, TM 2020, 'Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line', European Journal of Pharmaceutical Sciences, bind 148, 105315. https://doi.org/10.1016/j.ejps.2020.105315

APA

Nøhr-Nielsen, A., Bagger, S. O., Brünner, N., Stenvang, J., & Lund, T. M. (2020). Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. European Journal of Pharmaceutical Sciences, 148, [105315]. https://doi.org/10.1016/j.ejps.2020.105315

Vancouver

Nøhr-Nielsen A, Bagger SO, Brünner N, Stenvang J, Lund TM. Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. European Journal of Pharmaceutical Sciences. 2020;148. 105315. https://doi.org/10.1016/j.ejps.2020.105315

Author

Nøhr-Nielsen, Asbjørn ; Bagger, Sofie Otzen ; Brünner, Nils ; Stenvang, Jan ; Lund, Trine Meldgaard. / Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. I: European Journal of Pharmaceutical Sciences. 2020 ; Bind 148.

Bibtex

@article{36cfd6b707e045ad834af31f76bd5a4e,
title = "Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line",
abstract = "One of the primary barriers in treating cancer patients is the development of resistance to the available treatments. This is the case for treatment of triple negative breast cancer (TNBC) with docetaxel, which is part of the neoadjuvant treatment for TNBC. The novel compound SCO-101 is under investigation for its potential treatment effect in several types of drug resistant cancer. The aim of this study was to establish a pharmacodynamic model that captures the effect of docetaxel, SCO-101, and the combination on cell survival in docetaxel resistant MDA-MB-231 TNBC cells. Several combination models were compared and a recently published combination model, the general pharmacodynamic interaction model (GPDI), provided the best fit. The model allowed for description and quantification of the interaction between docetaxel and SCO-101 with respects to both maximal effect and potency. Based on this model, SCO-101 has a synergistic effect with docetaxel. This synergy is not present in the maximal effect, but the combination of SCO-101 and docetaxel showed an approximately 60{\%} increase in potency compared to docetaxel alone. Furthermore, the predicted model surface for the combination provided key information regarding promising dose ratios and dose levels for further studies of the combination. Lastly, the study presents a use case for the GPDI model, which provides a way to quantify and interpret drug-drug interactions.",
author = "Asbj{\o}rn N{\o}hr-Nielsen and Bagger, {Sofie Otzen} and Nils Br{\"u}nner and Jan Stenvang and Lund, {Trine Meldgaard}",
note = "Copyright {\circledC} 2020. Published by Elsevier B.V.",
year = "2020",
doi = "10.1016/j.ejps.2020.105315",
language = "English",
volume = "148",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line

AU - Nøhr-Nielsen, Asbjørn

AU - Bagger, Sofie Otzen

AU - Brünner, Nils

AU - Stenvang, Jan

AU - Lund, Trine Meldgaard

N1 - Copyright © 2020. Published by Elsevier B.V.

PY - 2020

Y1 - 2020

N2 - One of the primary barriers in treating cancer patients is the development of resistance to the available treatments. This is the case for treatment of triple negative breast cancer (TNBC) with docetaxel, which is part of the neoadjuvant treatment for TNBC. The novel compound SCO-101 is under investigation for its potential treatment effect in several types of drug resistant cancer. The aim of this study was to establish a pharmacodynamic model that captures the effect of docetaxel, SCO-101, and the combination on cell survival in docetaxel resistant MDA-MB-231 TNBC cells. Several combination models were compared and a recently published combination model, the general pharmacodynamic interaction model (GPDI), provided the best fit. The model allowed for description and quantification of the interaction between docetaxel and SCO-101 with respects to both maximal effect and potency. Based on this model, SCO-101 has a synergistic effect with docetaxel. This synergy is not present in the maximal effect, but the combination of SCO-101 and docetaxel showed an approximately 60% increase in potency compared to docetaxel alone. Furthermore, the predicted model surface for the combination provided key information regarding promising dose ratios and dose levels for further studies of the combination. Lastly, the study presents a use case for the GPDI model, which provides a way to quantify and interpret drug-drug interactions.

AB - One of the primary barriers in treating cancer patients is the development of resistance to the available treatments. This is the case for treatment of triple negative breast cancer (TNBC) with docetaxel, which is part of the neoadjuvant treatment for TNBC. The novel compound SCO-101 is under investigation for its potential treatment effect in several types of drug resistant cancer. The aim of this study was to establish a pharmacodynamic model that captures the effect of docetaxel, SCO-101, and the combination on cell survival in docetaxel resistant MDA-MB-231 TNBC cells. Several combination models were compared and a recently published combination model, the general pharmacodynamic interaction model (GPDI), provided the best fit. The model allowed for description and quantification of the interaction between docetaxel and SCO-101 with respects to both maximal effect and potency. Based on this model, SCO-101 has a synergistic effect with docetaxel. This synergy is not present in the maximal effect, but the combination of SCO-101 and docetaxel showed an approximately 60% increase in potency compared to docetaxel alone. Furthermore, the predicted model surface for the combination provided key information regarding promising dose ratios and dose levels for further studies of the combination. Lastly, the study presents a use case for the GPDI model, which provides a way to quantify and interpret drug-drug interactions.

U2 - 10.1016/j.ejps.2020.105315

DO - 10.1016/j.ejps.2020.105315

M3 - Journal article

C2 - 32201343

VL - 148

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

M1 - 105315

ER -

ID: 238426642